...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Pharmacy and Pharmaceutical Sciences >Statins Against Drug-Induced Nephrotoxicity
【24h】

Statins Against Drug-Induced Nephrotoxicity

机译：他汀类药物抗药性肾毒性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Drug-induced nephrotoxicity (DIN) accounts for up to 60% of hospital acquired acute kidney injury with considerable morbidity and mortality. Several efforts have been made to reduce drug-induced nephrotoxicity; however, DIN remains a matter of concern. Statins with their antioxidant, anti-inflammatory and anti-apoptotic effects may have the potential to protect kidney against DIN. The present review evaluated all of the available in vitro and in vivo studies that examined the use of statins as renoprotective agents against nephrotoxic drugs. Materials for this review were obtained by searching Medline, PubMed, Scopus, Cochrane central register of controlled trials, and Cochrane database of systematic reviews. Key words used as search terms included “statin”, “3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, “HMG-CoA reductase inhibitors”, “nephroprotective”, “renoprotective”, “drug-induced renal diseases”, “drug-induced nephrotoxicity”, “drug-induced renal toxicity”, “drug-induced nephropathy”, “drug-induced renal side effects”, and “contrast-induced nephropathy”. This search was performed without time limitation. Only English language articles were included in this review. This review concluded that chronic statin user may be less prone to contrast-induced nephropathy (CIN) compared with statin non-users. Short-term high dose statin administration may also reduce the incidence of CIN in statin na?ve patients. This renoprotective effect of statins against CIN is seen in low risk patients with normal kidney function or mild kidney dysfunction, but probably not in patients with moderate to severe renal dysfunction. Based on available animal data, statins may protect kidney against gentamicin-, cisplatin- and cyclosporine-induced nephrotoxicity, however, theses animal results have not yet been confirmed by human data. This article is open to POST-PUBLICATION REVIEW . Registered readers (see “For Readers”) may comment by clicking on on the issue’s contents page.
机译：药物性肾毒性（DIN）占医院获得性急性肾损伤的60％，具有较高的发病率和死亡率。为了减少药物引起的肾毒性已经做出了一些努力。但是，DIN仍然值得关注。他汀类药物具有抗氧化，抗炎和抗凋亡的作用，可能具有保护肾脏免受DIN损害的潜力。本评价评估了所有可用的体外和体内研究，这些研究检查了他汀类药物作为针对肾毒性药物的肾脏保护剂的用途。通过搜索Medline，PubMed，Scopus，Cochrane对照试验中央注册系统和系统评价的Cochrane数据库，可获得用于该评价的材料。用作搜索词的关键词包括“他汀”，“ 3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂”，“ HMG-CoA还原酶抑制剂”，“保护肾”，“保护肾”，“药物引起的肾脏疾病”，“药物引起的肾毒性”，“药物引起的肾毒性”，“药物引起的肾病”，“药物引起的肾副作用”和“造影剂引起的肾病”。该搜索没有时间限制。该评论仅包括英语文章。这项审查得出的结论是，与非他汀类药物使用者相比，慢性他汀类药物使用者较不容易产生对比剂诱发的肾病（CIN）。短期大剂量他汀类药物的给药也可以降低未接受他汀类药物的患者中CIN的发生率。他汀类药物对CIN的这种肾脏保护作用在肾功能正常或轻度肾功能不全的低风险患者中可见，但在中度至重度肾功能不全的患者中可能没有。根据现有的动物数据，他汀类药物可能保护肾脏免受庆大霉素，顺铂和环孢素诱导的肾毒性，但是，这些动物结果尚未得到人类数据的证实。本文对POST-PUBLICATION REVIEW开放。已注册的读者（请参阅“针对读者”）可以通过单击问题的内容页面来发表评论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号